Co-Authors
This is a "connection" page, showing publications co-authored by DEBORAH A KUBAN and SEUNGTAEK CHOI.
Connection Strength
1.507
-
Assessing the Quality of a Radiation Oncology Case-Based, Peer-Review Program in an Integrated Academic and Community Cancer Center Network. J Oncol Pract. 2016 Apr; 12(4):e476-86.
Score: 0.136
-
Local recurrence map to guide target volume delineation after radical prostatectomy. Pract Radiat Oncol. 2014 Nov-Dec; 4(6):e239-46.
Score: 0.119
-
Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1074-84.
Score: 0.119
-
Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients. Prostate Cancer Prostatic Dis. 2013 Dec; 16(4):346-51.
Score: 0.114
-
Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. Cancer. 2013 Sep 15; 119(18):3265-71.
Score: 0.113
-
PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era. Int J Radiat Oncol Biol Phys. 2013 Jan 01; 85(1):e39-46.
Score: 0.108
-
Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int J Radiat Oncol Biol Phys. 2013 Mar 01; 85(3):693-9.
Score: 0.106
-
Prostate cancer-specific mortality after definitive radiation therapy: who dies of disease? Eur J Cancer. 2012 Jul; 48(11):1664-71.
Score: 0.102
-
Improvement in prostate cancer survival over time: a 20-year analysis. Cancer J. 2012 Jan-Feb; 18(1):1-8.
Score: 0.102
-
Toxicity associated with postoperative radiation therapy for prostate cancer. Am J Clin Oncol. 2011 Dec; 34(6):611-8.
Score: 0.101
-
Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys. 2011 Apr 01; 79(5):1310-7.
Score: 0.091
-
Quantification of prostate and seminal vesicle interfraction variation during IMRT. Int J Radiat Oncol Biol Phys. 2008 Jul 01; 71(3):813-20.
Score: 0.077
-
Proton therapy toxicity outcomes for localized prostate cancer: Long-term results at a comprehensive cancer center. Clin Transl Radiat Oncol. 2024 Sep; 48:100822.
Score: 0.061
-
Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76.
Score: 0.032
-
Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Dec 01; 87(5):946-53.
Score: 0.029
-
Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer. Ann Oncol. 2012 Sep; 23(9):2346-2352.
Score: 0.026
-
Long-term tumor control after brachytherapy for base-of-prostate cancer. J Contemp Brachytherapy. 2011 Dec; 3(4):183-7.
Score: 0.025
-
Dosimetric impact of fiducial markers in patients undergoing photon beam radiation therapy. Phys Med. 2012 Jul; 28(3):240-4.
Score: 0.025
-
A volumetric trend analysis of the prostate and seminal vesicles during a course of intensity-modulated radiation therapy. Am J Clin Oncol. 2010 Apr; 33(2):173-5.
Score: 0.023